Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients.
agonism, cancer, co-stimulation, immunotherapy, TNFR
Dadas, Osman
0d1fce01-fcba-442c-9fa5-1972dbb96fd6
Ertay, Ayse
73607145-329d-49bb-9506-5972b8c0e434
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
25 April 2023
Dadas, Osman
0d1fce01-fcba-442c-9fa5-1972dbb96fd6
Ertay, Ayse
73607145-329d-49bb-9506-5972b8c0e434
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Dadas, Osman, Ertay, Ayse and Cragg, Mark S.
(2023)
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.
Frontiers in Immunology, 14, [1147467].
(doi:10.3389/fimmu.2023.1147467).
Abstract
The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy is attractive, although to date, under-exploited. In this review we discuss the importance of co-stimulatory members of the TNFRSF in optimal immune response generation, the rationale behind targeting these receptors for immunotherapy, the success of targeting them in pre-clinical studies and the challenges in translating this success into the clinic. The efficacy and limitations of the currently available agents are discussed alongside the development of next generation immunostimulatory agents designed to overcome current issues, and capitalize on this receptor class to deliver potent, durable and safe drugs for patients.
Text
Revised Mar 2023 - Dadas et al. 2023 - Manuscript
- Accepted Manuscript
Text
fimmu-14-1147467
- Version of Record
More information
Accepted/In Press date: 27 March 2023
Published date: 25 April 2023
Additional Information:
Funding Information:
MC acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent International and has received research funding from BioInvent International, GSK, UCB, iTeos, and Roche and receives institutional payments and royalties from patents and licenses relating to antibody immunotherapy. OD has received research funding from BioInvent International, outside of the current work.
Funding Information:
This work was supported by Cancer Research UK funding received by MC. Acknowledgments
Publisher Copyright:
Copyright © 2023 Dadas, Ertay and Cragg.
Keywords:
agonism, cancer, co-stimulation, immunotherapy, TNFR
Identifiers
Local EPrints ID: 477450
URI: http://eprints.soton.ac.uk/id/eprint/477450
ISSN: 1664-3224
PURE UUID: 0393a57f-2849-4776-bfaf-1bc23d967df2
Catalogue record
Date deposited: 06 Jun 2023 17:06
Last modified: 17 Mar 2024 02:46
Export record
Altmetrics
Contributors
Author:
Osman Dadas
Author:
Ayse Ertay
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
